Literature DB >> 16845209

Age-related macular degeneration (AMD): pathogenesis and therapy.

Jerzy Z Nowak1.   

Abstract

Age-related macular degeneration (AMD) is a disease leading to severe visual loss and legal blindness in the elderly population. Its pathogenesis, likely multifactorial, involving a complex interaction of metabolic, functional, genetic and environmental factors, remains poorly understood. For these reasons currently used therapeutic approaches are insufficiently effective. Although major abnormalities are seen in four functionally interrelated tissues, i.e., photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane and choriocapillaries, the impairment of RPE cell functions is an early and crucial event in the molecular pathways leading to clinically relevant AMD changes. RPE progressively degenerate, which results in a progressive irreversible degeneration of photoreceptors. Four processes: lipofuscinogenesis, drusogenesis, inflammation and neovascularization, specifically contribute to the development of two forms of AMD, the dry form (non-exudative; geographic atrophy) and the wet form (exudative, neovascular). This paper briefly describes major molecular and cellular events leading to AMD, and presents currently used and new experimental, forthcoming therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845209

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  206 in total

1.  Treatment of dry age-related macular degeneration with dobesilate.

Authors:  P Cuevas; L A Outeiriño; J Angulo; G Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2012-06-21

Review 2.  Oxidative stress and the ubiquitin proteolytic system in age-related macular degeneration.

Authors:  Scott M Plafker
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 3.  Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors:  An Truong; Tien Y Wong; Levon M Khachigian
Journal:  J Mol Med (Berl)       Date:  2010-12-18       Impact factor: 4.599

4.  Absence of DJ-1 causes age-related retinal abnormalities in association with increased oxidative stress.

Authors:  Vera L Bonilha; Brent A Bell; Mary E Rayborn; Ivy S Samuels; Anna King; Joe G Hollyfield; Chengsong Xie; Huaibin Cai
Journal:  Free Radic Biol Med       Date:  2017-01-11       Impact factor: 7.376

5.  [Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].

Authors:  E Matthé; D Sandner
Journal:  Ophthalmologe       Date:  2011-04       Impact factor: 1.059

6.  Porous poly(ε-caprolactone) scaffolds for retinal pigment epithelium transplantation.

Authors:  Kevin J McHugh; Sarah L Tao; Magali Saint-Geniez
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-25       Impact factor: 4.799

Review 7.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

8.  Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.

Authors:  Thomas A Vo; Sina Abedi; Kevin Schneider; Marilyn Chwa; M Cristina Kenney
Journal:  Exp Eye Res       Date:  2018-07-30       Impact factor: 3.467

9.  Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner.

Authors:  Kusumam Joseph; Liudmila Kulik; Beth Coughlin; Kannan Kunchithapautham; Mausumi Bandyopadhyay; Steffen Thiel; Nicole M Thielens; V Michael Holers; Bärbel Rohrer
Journal:  J Biol Chem       Date:  2013-03-14       Impact factor: 5.157

10.  Laser-Induced Choroidal Neovascularization in Rats.

Authors:  Min Zhao; Wankun Xie; Travis W Hein; Lih Kuo; Robert H Rosa
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.